HOME >> BIOLOGY >> NEWS
'High efficiency' vacuum cleaners no better at protecting against dust mites

Researchers at the North West Lung Centre, run by The University of Manchester and based at Wythenshawe Hospital, have discovered that vacuum cleaners with 'high-efficiency particulate air' or HEPA filters are no more effective than standard models at reducing exposure to dust-mites.

The team compared nasal air samples taken before and during vacuum cleaning using both HEPA and non-HEPA vacuum cleaners. They found a small increase in exposure to dust-mite during vacuuming with either type of machine, which was increased when emptying the dust compartments of either.

Lead investigator Dr Robin Gore said: "These vacuum cleaners are marketed to allergy-sufferers on the basis that they reduce a person's exposure to air-borne particles raised from carpeted floors. For allergy sufferers, such particles can trigger asthma attacks. However, we have already found that both HEPA- and non-HEPA vacuum cleaners can actually increase an individual's exposure to particles containing cat allergens.

"These latest findings further suggest that there is no significant advantage to using a HEPA vacuum cleaner to reduce exposure to air-borne particles like dust-mites.

"In combination with our previous work, the study seems to confirm that high-efficiency vacuum cleaners confer no benefits and should not currently be specifically recommended to allergy sufferers as a means of reducing personal exposure to allergens, either by their manufacturers or health professionals."

The study was published in the January 2006 issue of the European Journal of Allergy and Clinical Immunology. The co-investigators in the study were Professors Ashley Woodcock and Adnan Custovic.


'"/>

Contact: Jo Nightingale
jo.nightingale@manchester.ac.uk
161-275-8156
University of Manchester
13-Feb-2006


Page: 1

Related biology news :

1. Innovative tagging technique may help researchers better protect fish stocks
2. Gene predicts better outcome as cortex normalizes in teens with ADHD
3. Handicapping tuberculosis may be the way to a better vaccine
4. Military to study better pain relief in battle zones
5. Wider buffers are better
6. More fish oil, less vegetable oil, better for your health
7. Losing weight after pregnancy -- diet and exercise better than diet alone
8. Decoding mushrooms secrets could combat carbon, find better biofuels and safer soils
9. Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
10. Weeds survive the wild better than natives
11. Doing nature one better: Expanding the genetic code in living mammalian cells

Post Your Comments:
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , ... problems, is pleased to announce their ranking as one of the top 5000 companies ... fastest-growing private companies across the nation. , “It is truly an honor to be ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
(Date:8/27/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that executives from the company will ... September.  , Pedro Lichtinger , ... 17th Annual Global Investment Conference on Wednesday, September 10, ... Hotel in New York City . ...
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
Cached News: